Angiopoietin-1 in the treatment of ischemia and sepsis

Nathan M. Novotny, Tim Lahm, Troy A. Markel, Paul R. Crisostomo, Meijing Wang, Yue Wang, Jiangning Tan, Daniel R. Meidrum

Research output: Contribution to journalReview article

21 Scopus citations


Angiogenic factors have been the focus of a great deal of research for the treatment of ischemic diseases. Described just more than 10 years ago, angiopoietin 1 (Ang-1) has shown promising results in l/R models. Angiopoietin 1 is essential for both embryonic vasculogenesis and adult angiogenesis. Because of its role in maturation of vessels, it seems well suited to complement the angiogenic factor vascular endothelial growth factor (VEGF), which has been shown to induce vascular budding but in isolation produces nonfunctional vessels. This review will focus on (1) Ang-1 and its receptor, Tie-2, and the resultant intracellular signaling cascade; (2) the complex relationship of Ang-1 and VEGF; (3) the results of Ang-1 in l/R and sepsis models; (4) the results of combination (Ang-1 and VEGF) therapies in l/R and sepsis models; and (5) delivery mechanisms for angiogenic factors to ischemic heart.

Original languageEnglish (US)
Pages (from-to)335-341
Number of pages7
Issue number4
StatePublished - Apr 1 2009


  • Angiopoietin 1
  • Ischemia
  • Sepsis
  • Vascular endothelial growth factor
  • VEGF

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Fingerprint Dive into the research topics of 'Angiopoietin-1 in the treatment of ischemia and sepsis'. Together they form a unique fingerprint.

  • Cite this

    Novotny, N. M., Lahm, T., Markel, T. A., Crisostomo, P. R., Wang, M., Wang, Y., Tan, J., & Meidrum, D. R. (2009). Angiopoietin-1 in the treatment of ischemia and sepsis. Shock, 31(4), 335-341.